Evaluating NT-proBNP Levels in COPD Patients on Triple Inhalation Therapy
Change in Serum Levels of NT-proBNP During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.
This study is testing how a combination of three inhalers affects heart-related blood levels in people with COPD after three months of treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 29 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Istituto Nazionale di Ricovero e Cura per Anziani Academic / other |
| Locations | 2 sites (Ancona and 1 other locations) |
| Trial ID | NCT06317428 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess serum NT-proBNP levels in patients with Chronic Obstructive Pulmonary Disease (COPD) after three months of treatment with a combination of formoterol, glycopyrrolate, and budesonide. The study will involve monitoring these patients to understand the impact of this triple therapy on NT-proBNP levels, which may indicate heart strain or failure. By focusing on a specific population, the study seeks to provide insights into the cardiovascular effects of this inhalation therapy in COPD management.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with COPD who have a clinical indication for triple inhalation therapy.
Not a fit: Patients with a life expectancy of less than one year may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify cardiovascular risks in COPD patients undergoing triple therapy, leading to improved management strategies.
How similar studies have performed: While similar studies have explored the effects of COPD treatments, this specific evaluation of NT-proBNP levels in relation to triple therapy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * COPD; * Clinical indication for triple inhalation therapy with formoterol/glycopyrrolate/budesonide; Exclusion Criteria: * Life expectancy less than one year;
Where this trial is running
Ancona and 1 other locations
- INRCA Hospital — Ancona, Italy (Recruiting)
- IRCCS INRCA Hospital — Osimo, Italy (Recruiting)
Study contacts
- Study coordinator: Anna Rita Bonfigli
- Email: a.bonfigli@inrca.it
- Phone: 0718003719
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.